About Mereo Biopharma Group plc (adapted from Mereo Biopharma Group plc prospectus):
They are a multi-asset biopharmaceutical company focused on the acquisition, development, and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare and specialty diseases. This is an IPO of the company's ADSs. Their ordinary shares trade on AIM, a market of the London Stock Exchange, under the symbol MPH. There is a concurrent private placement in Europe associated with this deal.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.